Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PMD Stock Forecast 2026-2027
$2.21
Current Price
$13.50M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PMD Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PMD Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-4.3%
1 Year Change
0.0%
Year-to-Date Change
-32.0%
From 52W High of $3.25
+99.1%
From 52W Low of $1.11
📊 TOP ANALYST CALLS
Did PMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Psychemedics is one of their latest high-conviction picks.
Latest PMD Stock Price Targets & Analyst Predictions
PMD has shown a year-to-date change of 0.0% and a 1-year change of -4.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PMD. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PMD Analyst Ratings
0
Buy
0
Hold
0
Sell
PMD Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.21
Latest PMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Psychemedics Corporation (PMD) Competitors
The following stocks are similar to Psychemedics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Psychemedics Corporation (PMD) Financial Data
Valuation Metrics
Market Cap
$13.50M
Enterprise Value
$13.25M
P/E Ratio
N/A
PEG Ratio
N/A
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
-14.5%
Gross Margin
+31.4%
Operating Margin
-9.6%
Net Margin
+36.1%
EPS Growth
-11.5%
Financial Health
Cash/Price Ratio
N/A
Current Ratio
1.8x
Debt/Equity
0.2x
ROE
-36.3%
ROA
-22.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Psychemedics Corporation (PMD) Business Model
About Psychemedics Corporation
What They Do
Provides drug testing services using hair analysis.
Business Model
The company generates revenue by offering drug testing services that analyze hair samples for various substances, including illegal drugs and prescription medications. Its testing is aimed at employers, treatment professionals, law enforcement, and parents, providing both screening and confirmation of drug use, which helps in making informed decisions regarding hiring, treatment, and safety.
Additional Information
Founded in 1986 and based in Dallas, Texas, the company utilizes mass spectrometry for accurate testing and provides detailed quantitative results that reflect drug usage patterns over time. This positions Psychemedics as a vital resource in the growing market for drug testing and health monitoring.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
116
CEO
Mr. Brian Hullinger
Country
United States
IPO Year
1994
Website
www.psychemedics.comPsychemedics Corporation (PMD) Latest News & Analysis
Latest News
Psychemedics Releases 2025 Workforce Insights Report
10 months ago
Quick Summary
Psychemedics Corporation released its 2025 Workforce Insights Report, analyzing hair drug testing results from 2024, highlighting trends in workplace safety and employer risk across various sectors.
Why It Matters
The report offers critical data on drug trends affecting workforce safety and hiring, signaling potential risks or opportunities for sectors relying on drug testing, influencing investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Psychemedics Corporation has been awarded "Most Innovative Drug Testing Company of the Year" by Acquisition International Magazine for its advancements in drug detection and Enhanced Quartile Reporting.
Why It Matters
Psychemedics' award highlights its innovation and leadership in drug testing, potentially boosting its market reputation and attracting investment interest, impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Psychemedics Corporation will implement a 1-for-5,000 reverse stock split followed by a 5,000-for-1 forward stock split, effective December 3, 2024, to maintain its Nasdaq listing.
Why It Matters
The 1-for-5,000 reverse split followed by a 5,000-for-1 forward split indicates significant restructuring, potentially impacting stock liquidity and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Psychemedics Corporation (NASDAQ: PMD) reported its third-quarter financial results for the period ending September 30, 2024.
Why It Matters
Psychemedics' Q3 financial results can influence investor sentiment, reflecting the company's performance and potential growth in the drug testing market, impacting stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Psychemedics Corporation (NASDAQ: PMD) has released its first Education Insights Report, highlighting its leadership in drug abuse hair testing.
Why It Matters
Psychemedics' new Education Insights Report may enhance its market position and attract clients, potentially driving revenue growth and impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Psychemedics Corporation (NASDAQ: PMD) reported its financial results for Q2 2024, ending June 30. Further details on performance were not included in the excerpt.
Why It Matters
Psychemedics' Q2 financial results may impact stock performance, reflecting company health and market demand for drug testing services. Strong results could drive investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PMD Stock
What is Psychemedics Corporation's (PMD) stock forecast for 2026?
Analyst forecasts for Psychemedics Corporation (PMD) are not currently available. The stock is trading at $2.21.
Is PMD stock a good investment in 2026?
Analyst ratings for PMD are not currently available. The stock is currently trading at $2.21. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PMD stock?
Price predictions from Wall Street analysts for PMD are not currently available. The stock is trading at $2.21.
What is Psychemedics Corporation's business model?
The company generates revenue by offering drug testing services that analyze hair samples for various substances, including illegal drugs and prescription medications. Its testing is aimed at employers, treatment professionals, law enforcement, and parents, providing both screening and confirmation of drug use, which helps in making informed decisions regarding hiring, treatment, and safety.
What is the highest forecasted price for PMD Psychemedics Corporation?
Price targets from Wall Street analysts for PMD are not currently available. The stock is trading at $2.21.
What is the lowest forecasted price for PMD Psychemedics Corporation?
Price targets from Wall Street analysts for PMD are not currently available. The stock is trading at $2.21.
What is the overall PMD consensus from analysts for Psychemedics Corporation?
Analyst ratings for PMD are not currently available. The stock is trading at $2.21.
How accurate are PMD stock price projections?
Stock price projections, including those for Psychemedics Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 7:27 PM UTC